Journal of Controlled Release, Год журнала: 2025, Номер unknown, С. 113752 - 113752
Опубликована: Апрель 1, 2025
Язык: Английский
Journal of Nanobiotechnology, Год журнала: 2024, Номер 22(1)
Опубликована: Фев. 14, 2024
Abstract Despite recent advancements in cancer treatment, this disease still poses a serious threat to public health. Vaccines play an important role preventing illness by preparing the body's adaptive and innate immune responses combat diseases. As our understanding of malignancies their connection system improves, there has been growing interest priming fight more effectively comprehensively. One promising approach involves utilizing nanoparticle systems for antigen delivery, which shown potentiate as vaccines and/or adjuvants. In review, we comprehensively summarized immunological mechanisms while focusing specifically on applications various types nanoparticles field immunotherapy. By exploring these breakthroughs, hope identify significant challenges obstacles making nanoparticle-based adjuvants feasible clinical application. This review serves assess breakthroughs vaccinations shed light prospects potential barriers. doing so, aim inspire future immunotherapies that harness nanotechnology deliver effective targeted treatments. Graphical abstract
Язык: Английский
Процитировано
29
Chemical Society Reviews, Год журнала: 2023, Номер 52(15), С. 5172 - 5254
Опубликована: Янв. 1, 2023
This review provides an introduction of basic principles adjuvanted human vaccines in clinics and summarizes emerging nanotechnology adjuvants vaccine development against cancer infectious diseases.
Язык: Английский
Процитировано
40
Advanced Science, Год журнала: 2023, Номер 10(26)
Опубликована: Июль 6, 2023
The advent of immunotherapy has marked a new era in cancer treatment, offering significant clinical benefits. Cell membrane as drug delivery materials played crucial role enhancing therapy because their inherent biocompatibility and negligible immunogenicity. Different cell membranes are prepared into nanovesicles (CMNs), but CMNs have limitations such inefficient targeting ability, low efficacy, unpredictable side effects. Genetic engineering deepened the critical immunotherapy, enabling genetically engineered-CMN (GCMN)-based therapeutics. To date, that surface modified by various functional proteins been developed through genetic engineering. Herein, brief overview strategies for features sources is discussed, followed description GCMN preparation methods. application GCMNs directed at different immune targets addressed challenges prospects translation.
Язык: Английский
Процитировано
34
Biomaterials Research, Год журнала: 2023, Номер 27(1)
Опубликована: Фев. 9, 2023
Cancer is a complex illness that presents significant challenges in its understanding and treatment. The classic definition, "a group of diseases characterized by the uncontrolled growth spread abnormal cells body," fails to convey intricate interaction between many entities involved cancer. Recent advancements field cancer research have shed light on role played individual tumor microenvironment as whole development progression. This breakthrough enables utilization components biological tools, opening new possibilities. article delves deeply into concept "tumor-derived systems", an umbrella term for tools sourced from aid combatting it. It includes cell membrane-coated nanoparticles (for theranostics), extracellular vesicles diagnosis/therapy), lysates vaccine development), engineered cells/organoids research). review seeks offer complete overview tumor-derived materials are utilized research, well their current stages implementation. aimed primarily at researchers working interface biology biomedical engineering, it provides vital insights this fast-growing topic.
Язык: Английский
Процитировано
26
Exploration, Год журнала: 2024, Номер 4(6)
Опубликована: Март 28, 2024
Abstract Because therapeutic cancer vaccines can, in theory, eliminate tumor cells specifically with relatively low toxicity, they have long been considered for application repressing progression. Traditional containing a single or few discrete epitopes failed the clinic, possibly due to challenges epitope selection, target downregulation, cell heterogeneity, microenvironment immunosuppression, lack of vaccine immunogenicity. Whole membrane vaccines, which provide rich source antigens, are emerging as viable alternatives. Autologous and allogenic cellular evaluated clinical treatments. Tumor membranes (TCMs) an intriguing antigen source, membrane‐accessible targets and, at same time, serve integrated carriers adjuvants other agents. This review provides summary properties technologies TCM vaccines. Characteristics, categories, mechanisms, preparation methods discussed, demonstrable additional benefits derived from combining chemotherapy, sonodynamic therapy, phototherapy, oncolytic viruses. Further research chemistry, biomedicine, immunology, bioinformatics address current drawbacks could facilitate adoption
Язык: Английский
Процитировано
16
Chemical Society Reviews, Год журнала: 2024, Номер 53(11), С. 5862 - 5903
Опубликована: Янв. 1, 2024
Schematic of the immunomodulatory approaches for tipping balance towards anti-cancer immunity. This image was created with BioRender.com.
Язык: Английский
Процитировано
11
Journal of Controlled Release, Год журнала: 2025, Номер 380, С. 17 - 35
Опубликована: Фев. 3, 2025
Язык: Английский
Процитировано
1
Advanced Functional Materials, Год журнала: 2023, Номер 34(7)
Опубликована: Ноя. 1, 2023
Abstract Circulating tumor cells (CTCs) are a crucial biomarker for early cancer diagnosis and progress of metastasis. However, the extremely rare CTCs with large amounts background leukocytes seriously restricte purity enriched CTCs. Herein, genetically engineered cell membrane‐coated magnetic nanoparticles following properties constructed: I) The leukocyte membrane camouflaged nanoparticles, which could significantly reduce nonspecific binding homologous achieve high‐purity isolation CTCs, prepared by simple one‐step extrusion II) cellular stably expressing single‐chain variable fragment (scFv) anti‐epidermal growth factor receptor (EGFR) antibody ensure recognition EGFR‐positive affinity resulting toward extracellular EGFR protein improved more than 100‐fold compared natural nanoparticles. Furthermore, commercial immunomagnetic functional achieved greater capture efficiency in artificial blood samples increased from 64.8% to 93.5%. Consequently, authors successfully isolate high pure 6 out patients using This platform exhibits promising potential CTC detection clinical samples, offering an innovative method prognosis evaluation.
Язык: Английский
Процитировано
22
ACS Nano, Год журнала: 2023, Номер 17(24), С. 24593 - 24618
Опубликована: Дек. 6, 2023
Tumor immunotherapy is a safe and effective strategy for precision medicine. However, most cancer cases still ends in failure, with the root causes of immunosuppressive extraordinary heterogeneity solid tumors microenvironment. The emerging biomimetic nanodelivery system provides promising tactic to improve effect while reducing adverse reactions on nontarget cells. Herein, we summarize relationship between tumor occurrence immune microenvironment, mechanism escape, classification (including adoptive cellular therapy, cytokines, vaccines, checkpoint inhibitors) recommend target cells first, then emphatically introduce recent advances applications latest systems (e.g., cells, erythrocytes, platelets, bacteria) immunotherapy. Meanwhile, separately application vaccines. Finally, predictable challenges perspectives forward exploration are also discussed.
Язык: Английский
Процитировано
22
Advanced Healthcare Materials, Год журнала: 2024, Номер 13(13)
Опубликована: Фев. 7, 2024
Cancer nanovaccines have attracted widespread attention by inducing potent cytotoxic T cell responses to improve immune checkpoint blockade (ICB) therapy, while the lack of co-stimulatory molecules limits their clinical applications. Here, a genetically engineered cancer cytomembrane nanovaccine is reported that simultaneously overexpresses molecule CD40L and inhibitor PD1 elicit robust antitumor immunity for immunotherapy. The tumor antigens inherited from cytomembranes effectively stimulate dendritic (DC)-mediated activation cells, on significantly blocks PD1/PD-L1 signaling pathway, synergistically stimulating responses. Benefiting targeting ability cytomembranes, this formula shows an enhanced lymph node trafficking retention. Compared with original induces twofold DC maturation satisfactory precaution efficacy in breast mouse model. This offers simple, safe, strategy incorporating components
Язык: Английский
Процитировано
9